Clinical Trial Update: Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for Seneca Valley Virus-001 with Cyclophosphamide in pediatric patients with relapsed/refractory neuroblastoma, rhabdomyosarcoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma
• Gastrointestinal Carcinoid Tumor
• Neuroblastoma
• Neuroendocrine Tumor
• Renal Cell Carcinoma
• Retinoblastoma
• Rhabdomyosarcoma
• Sarcoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Seneca Valley Virus-001

Snippet

Sponsor: Children's Oncology Group | Conditions: Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor | Phase 1 | Status: COMPLETED